Meeting
2019 ASCO Annual Meeting
c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer.
Authors
Rebecca Suk Heist
Massachusetts General Hospital Cancer Center, Boston, MA
Rebecca Suk Heist , Monica Motwani , Fabrice Barlesi , Jonathan Wade Goldman , Karen Kelly , Yan Sun , Jun Wu , Bruce Allen Bach , D. Ross Camidge
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02099058
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9023)
DOI
10.1200/JCO.2019.37.15_suppl.9023
Abstract #
9023
Poster Bd #
346
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
First Author: Jonathan W. Goldman
Poster
2017 ASCO Annual Meeting
Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).
First Author: ERIC ANGEVIN
Poster
2019 ASCO Annual Meeting
Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.
First Author: D. Ross Camidge
Poster
2024 ASCO Annual Meeting
Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).
First Author: Shen Zhao